Company news
Roche Holding Ltd (SIX:RO) news
Every Roche Holding Ltd press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarci...
August 26, 2026
Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care
August 24, 2026
Genentech Announces Manufacturing Expansion in Hillsboro, Oregon
August 20, 2026
Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility
August 18, 2026
Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis
July 24, 2026
Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow...
July 22, 2026
Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America
July 20, 2026
FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy
July 15, 2026
Roche receives CE Mark for blood test to identify tuberculosis infection
July 9, 2026
Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC
July 7, 2026
Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC
July 7, 2026
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G1...
July 2, 2026
FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refrac...
June 18, 2026
Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer
June 12, 2026
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
June 11, 2026
FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer
June 11, 2026
Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection
June 4, 2026
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with pos...
June 2, 2026
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
June 1, 2026
Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management
May 27, 2026
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
May 19, 2026
FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
May 15, 2026
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
May 12, 2026
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
May 7, 2026
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
April 30, 2026
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
April 29, 2026
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign
April 24, 2026
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of ...
April 23, 2026
Roche's ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
April 22, 2026
Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
April 21, 2026
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
April 21, 2026
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
April 21, 2026
Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis
April 13, 2026
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrad...
April 9, 2026
Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply
March 30, 2026
/C O R R E C T I O N -- Roche/
March 24, 2026
Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and d...
March 23, 2026
Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation
March 18, 2026
Breakthrough at 2026 AACR! Senhwa Biosciences' CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy
March 17, 2026
Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions
March 16, 2026
AI in Life Sciences Market, 2026-2040 Industry Trends and Global Forecasts - IBM, IQVIA and Oracle Lead Data Platforms While Roche, Pfize...
March 13, 2026
FUJIFILM Biotechnologies Appoints Christiane Bardroff as Chief Business Officer
March 12, 2026
Roche Annual General Meeting 2026
March 10, 2026
Pegasys (Roche, pharmaand) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-203...
March 10, 2026
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
March 9, 2026
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity ...
March 6, 2026
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
March 5, 2026
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing an...
March 2, 2026
Volta Labs Ignites AGBT 2026 with Major Product Launches and Industry-Shaping Partnerships
February 26, 2026
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026